PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 10,866 shares, a decrease of 19.2% from the February 12th total of 13,443 shares. Currently, 27.2% of the shares of the company are sold short. Based on an average daily volume of 6,078 shares, the days-to-cover ratio is currently 1.8 days. Based on an average daily volume of 6,078 shares, the days-to-cover ratio is currently 1.8 days. Currently, 27.2% of the shares of the company are sold short.

Institutional Trading of PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. Jane Street Group LLC bought a new stake in PicoCELA Inc. (NASDAQ:PCLA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned approximately 18.92% of PicoCELA at the end of the most recent quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PicoCELA in a research report on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, PicoCELA currently has an average rating of “Sell”.

PicoCELA Stock Performance

NASDAQ PCLA opened at $2.25 on Friday. PicoCELA has a twelve month low of $2.25 and a twelve month high of $112.20. The firm has a 50-day simple moving average of $5.36 and a 200 day simple moving average of $9.18. The company has a current ratio of 2.13, a quick ratio of 1.57 and a debt-to-equity ratio of 0.02.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.